The in vitro activity of norfloxacin and six other antimicrobial agents was tested against 93 vibrio strains representing the currently described pathogenic Vibrio species. Norfloxacin had excellent activity against all species, with the following MICs for 90% of the strains: 0.016 ,ug/ml for Vibrio cholerae (including tetracycline-resistant V. cholerae 01 strains), 0.25 ,ug/ml for V. parahaemolyticus, and 0.063 ,ig/ml for V.
Tetracycline is currently the drug of choice for serious vibrio infections (10, 14) . Since 1978, however, an increasing number of Vibrio cholerae 01 strains have been identified that have plasmid-mediated resistance to multiple antibiotics, including tetracycline. These strains have been responsible for major epidemics in Tanzania (9) and Bangladesh (7) and are currently endemic in parts of Africa (J. G. Morris 503, 1984) . Appearance of these strains has prompted a search for alternative antimicrobial agents with activity against vibrios. Norfloxacin is a new carboxyquinoline derivative that has in vitro activity against a number of enteric pathogens, including campylobacter, salmonella, shigella, toxigenic Escherichia coli, yersinia, and, in testing involving a limited number of strains, V. parahaemolyticus and V. cholerae (4, 8, 11, 13) . In vitro activity against V. cholerae 01 would make norfloxacin an attractive drug for further study in areas with tetracycline-resistant cholera. Demonstration of activity against the other known pathogenic Vibrio species would also enhance the potential usefulness of norfloxacin as a broad-spectrum agent for treatment of bacterial gastroenteritis. In this study we compared the in vitro activity of norfloxacin to that of nalidixic acid, tetracycline, chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole, and gentamicin against 93 vibrio strains representing all known pathogenic Vibrio species (10 Results of the microtiter MIC assays are given in Tables 1  and 2 . All vibrio strains tested were susceptible to norfloxacin, with MICs of .0.5 pLg/ml. V. cholerae strains were very susceptible to the drug, with MICs of 0.016 ,ug/ml for 90% of the strains tested. The presence of an R factor did not influence the norfloxacin MICs. Only one V. cholerae strain had a norfloxacin MIC of >0.016 ,ug/ml: the MIC for this strain was 0.25 ,ug/ml, with a corresponding MIC of nalidixic acid of 32 jLg/ml. A significant inoculum effect was observed for one of the four V. cholerae 01 strains tested, with MICs of <0.008 ,ug/ml at 103 and 105 organisms per ml and 1.0 ,ug/ml at 107 organisms per ml. For one of the two V. parahaemolyticus strains tested, the MIC increased from 0.25 to 1.0 ,ug/ml with an increase in the inoculum from 105 to 107 organisms per ml. The MIC for the V. vulnificus strain increased from 0.031 ,ug/ml at 103 organisms per ml to 0.125 ,ug/ml at 105 organisms per ml and 1 ,ug/ml at 107 organisms per ml.
Our data indicate that norfloxacin may be a useful agent for treatment of cholera. Peak stool concentrations of the drug after a single 400-mg oral dose have been shown to range from 207 to 2,716 ,ug/g (5) , with mean peak concentrations in serum and tissue after the same dose of 1.45 and 1 ,ug/ml, respectively (1). While caution should be used in making comparisons between stool drug concentrations and standard MICs, these stool levels are well above the observed MIC of 0.016 jLg/ml for 90% of the V. cholerae strains tested. At an inoculum of 107 organisms per ml, which corresponds more closely with V. cholerae 01 counts in stools of infected persons (M. M. Levine, personal communication), the highest observed MIC was 1.0 pLg/ml. One V. cholerae 01 strain lacking a resistance plasmid had an MIC of nalidixic acid of 32 ,ug/ml, indicating that chromosomally mediated resistance to this class of antimicrobial agents does occur; the norfloxacin MIC for the strain (at a standard 105 inoculum) was 0.25 ,ug/ml. As cholera is primarily a disease of children in endemic areas (6) , current questions about safety in pediatric age groups will need to be resolved if norfloxacin is to be widely used as an anticholera agent. The observation that all pathogenic Vibrio species are susceptible to norfloxacin makes it attractive for use as a broad-spectrum agent in treatment of bacterial gastroenteritis. In the United States, persons living along the Gulf and mid-Atlantic coasts, particularly persons who enjoy eating shellfish, are at risk for gastrointestinal illnes caused by non-O1 V. cholerae, V. parahaemolyticus, V. mimicus, V. hollisae, and even V. cholerae 01 (10) . Although the incidence of infection with these species is relatively low when compared with other enteric pathogens such as campylobacters (3), it would be advantageous to have an antimicrobial agent that could provide coverage for vibrios along with other bacterial pathogens pending culture results. V. vulnificus, V. alginolyticus, and V. damsela have been associated with wound infections and septicemia (10) . Al- though MICs were within clinically attainable serum and tissue drug levels, the possible role of norfloxacin in treatment of these infections is less clear. For all of these species, further studies will be necessary to assess clinical efficacy.
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